{"nctId":"NCT00395694","briefTitle":"Clinical Evaluation of BW430C in Epilepsy","startDateStruct":{"date":"2006-08-07"},"conditions":["Epilepsy"],"count":102,"armGroups":[{"label":"lamictal","type":"EXPERIMENTAL","interventionNames":["Drug: lamictal"]}],"interventions":[{"name":"lamictal","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Epilepsy with partial seizures\n* Tonic clonic seizures\n* Generalized seizures of Lennox-Gastaut\n* Subjects whose seizures are easily recognizable at least one seizure per month and counts for 8 consecutive weeks prior to the start of the study drug.\n* Concurrent AEDs: Subjects taking concurrent VPA.\n\nExclusion criteria:\n\n* Previous participation in a study of Lamictal\n* Known hypersensitivity to any drugs\n* Pregnant women\n* nursing mothers\n* women who may be pregnant\n* women contemplating pregnancy during the study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment","description":"Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing \"rash\"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the \"Skin and Subcutaneous Tissue Disorders\" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment","description":"Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing \"rash\"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the \"Skin and Subcutaneous Tissue Disorders\" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Intensity of Rash (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment","description":"The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Drug-related and Not Related Rash Events (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment","description":"The adverse event of rash was considered to be drug-related when the Investigator answered \"Yes\" to the following question: \"Is there a reasonable possibility that the adverse event may have been caused by the investigational product?\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 50 Percent Reduction in Seizure Frequency for the Indicated Types of Seizures","description":"Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types; mental retardation or regression; and abnormal findings on an electroencephalogram (EEG), with paroxysms of fast activity and generalized slow spike-and-wave discharges.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"18.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Seizure Frequency of the Indicated Types of Seizures","description":"Percent change in seizure frequency was calculated as 100 \\* (pre-treatment seizures minus MP seizures)/pre-treatment seizures. Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types, mental retardation or regression, and abnormal findings on an ECG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"-11.1","spread":null},{"groupId":"OG002","value":"-9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"27.4","spread":null},{"groupId":"OG002","value":"36.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"12.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Rash Event (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase","description":"Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing \"rash\"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the \"Skin and Subcutaneous Tissue Disorders\" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase","description":"Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing \"rash\"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the \"Skin and Subcutaneous Tissue Disorders\" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Intensity of Rash (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase","description":"The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Drug-related and Not Related Rash Events (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase","description":"The adverse event of rash was considered to be drug-related when the Investigator answered \"Yes\" to the following question: \"Is there a reasonable possibility that the adverse event may have been caused by the investigational product?\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Rash Events (Including SJS and Any Other Serious Drug Eruption) Adjudicated by the Rash Adjudication Committee in Participants Taking VPA","description":"The rash adjudication committee reviewed all rash events from a dermatologic standpoint based on the nature, onset site, affected area, time to onset, outcome, and the investigator's comments to adjudicate whether or not the reported event was a drug eruption. A drug eruption is an eruption or a solitary lesion caused by a drug taken internally, often a result of allergic sensitization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Monocyte Values Outside the Normal Range (Shifted High) at Weeks 4 and 8","description":"Monocytes are a type of white blood cell (WBC; typically comprising 2%-8% of total WBCs) and are a part of the immune system. The normal range for adults is 0.2 to 0.95 \\* 10\\^3 cells per microliter (µL); the normal range for adolescents is 0 to 0.8 \\* 10\\^3 cells per µL. The monocyte count may increase during chronic inflammation, stress response, immune-mediated disease, viral fever, etc. The percentage of participants (par.) with monocyte values outside the normal range was calculated as 100 \\* (number of par. with monocyte values outside the normal range) divided by the total number of par.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Somnolence","Diarrhoea","Pyrexia"]}}}